Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 12 · newest first

  1. Disease control should be the goal of therapy for WM patientsBlood Advances · 2017
  2. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agentsBlood · 2017
  3. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaBlood · 2017
  4. An overview of the role of carfilzomib in the treatment of multiple myelomaExpert Opinion on Pharmacotherapy · 2017
  5. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal functionClinical Pharmacology Advances and Applications · 2017
  6. Gefitinib: an “orphan” drug for non-small cell lung cancerExpert Opinion on Orphan Drugs · 2017
  7. Mechanisms of bone destruction in multiple myelomaEuropean Journal of Cancer Care · 2017
  8. Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studiesLeukemia & lymphoma/Leukemia and lymphoma · 2017
  9. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupBlood Cancer Journal · 2017
  10. Daratumumab combinations: what can we learn?Blood · 2017
  11. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional casesLeukemia & lymphoma/Leukemia and lymphoma · 2017
  12. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growthBritish Journal of Haematology · 2017
  13. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapiesEuropean Journal Of Haematology · 2017
  14. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.BMC Cancer · 2017
  15. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialBritish Journal of Haematology · 2017
  16. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomibBlood Cancer Journal · 2017
  17. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefitBlood Cancer Journal · 2017
  18. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical EvaluationThe Oncologist · 2017
  19. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysisEuropean Journal Of Haematology · 2017
  20. Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatmentBlood Cancer Journal · 2017
  21. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapyAmerican Journal of Hematology · 2017
  22. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupLeukemia & lymphoma/Leukemia and lymphoma · 2017
  23. Cardiac and renal complications of carfilzomib in patients with multiple myelomaBlood Advances · 2017
  24. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyBritish Journal of Haematology · 2017
  25. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyBritish Journal of Haematology · 2017
  26. Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM ‐8 consensus panelBritish Journal of Haematology · 2017
  27. Emerging treatment approaches for myeloma-related bone diseaseExpert Review of Hematology · 2017
  28. Efficacy and safety of elotuzumab for the treatment of multiple myelomaExpert Opinion on Drug Safety · 2017
  29. Current treatment options and investigational drugs for Waldenstrom’s MacroglobulinemiaExpert Opinion on Investigational Drugs · 2017
  30. Brain Oscillations Elicited by the Cold Pressor Test: A Putative Index of Untreated Essential HypertensionInternational Journal of Hypertension · 2017
  31. Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORLeukemia · 2016
  32. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimensLeukemia & lymphoma/Leukemia and lymphoma · 2016
  33. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL AmyloidosisBlood · 2016
  34. Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG StudyBlood · 2016
  35. Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)Blood · 2016
  36. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of PolluxBlood · 2016
  37. Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)Blood · 2016
  38. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsBlood · 2016
  39. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myelomaBlood Cancer Journal · 2016
  40. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaHaematologica · 2016
  41. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemiaLeukemia & lymphoma/Leukemia and lymphoma · 2016
  42. High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myelomaBlood Cancer Journal · 2016
  43. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndromeHaematologica · 2016
  44. Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine · 2016
  45. Current treatments for renal failure due to multiple myelomaExpert Opinion on Pharmacotherapy · 2016
  46. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcomeHematological Oncology · 2016
  47. Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple MyelomaRadiology · 2016
  48. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple MyelomaJournal of Clinical Oncology · 2016
  49. Carfilzomib for treating myelomaExpert Opinion on Orphan Drugs · 2016
  50. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7Blood · 2016